Company intelligence / Profile preview

C4 Imaging

Bellaire, Texas, USA

Ownership: Private
Employees: ~10
Development stage: Other

Overview

C4 Imaging has received FDA 510(k) clearance for its primary products. Clinical data and publications indicate that their Sirius MRI Marker enables precise post-implant MRI-based localization of brachytherapy seeds, improving quality assurance for radiotherapy in prostate cancer. Orion and Nova products extend utility to HDR brachytherapy and multi-modality imaging. No active clinical trials are currently listed on ClinicalTrials.gov[2][3][4][9].

Therapeutic areas: Oncology
Modalities: Device
Industry: Implantable Medical Devices

Partnerships

Isoray Medical (collaboration for Sirius MRI Marker with their Cesium-131 seeds)[4]Theragenics Corporation (sales/marketing for Orion Marker)[4]Evonik Corporation (polymer technology supply for Sirius)[4]AnazaoHealth Corporation (loading Sirius MRI Marker with brachytherapy strands)[4]

Beyond the preview

Go deeper on C4 Imaging.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on C4 Imaging.

Explore the full profile